Preparation and in vitro/in vivo evaluation of rofecoxib containing bovine serum albumin microspheres

Demirturk E., Gulsun T., Cayli Y., İZAT N., ŞAHİN S., ÖNER L.

Latin American Journal of Pharmacy, vol.36, no.6, pp.1096-1104, 2017 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 6
  • Publication Date: 2017
  • Journal Name: Latin American Journal of Pharmacy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1096-1104
  • Keywords: BCS Class II, In vitro-in vivo correlation, Microspheres, Rofecoxib
  • Hacettepe University Affiliated: Yes


© 2017, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.Rofecoxib, apart from its antiinflamatory, analgesic and antipyretic activity, is a Class II drug according to the BCS and suitable for being formulated as microspheres with bovine serum albumin. In this study, rofecoxib microsphere formulations were developed and characterized. One of the prepared formulations that has a particle size of 13.48 ± 2.11 μm, 35.20 ± 1.32% of encapsulation efficiency and bet-ter-sustained release (up to 18 h) was chosen for the in vivo experiments. A Level A IVIVC was evaluated between the in vitro dissolution and in vivo plasma concentration-time profile data. Linear regression analysis showed a statistically significant relationship between the in vitro dissolved percentages and in vivo absorbed percentages of the drug and the best fitted equation was described.